Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
NCT04129944 is registered in ClinicalTrials.gov with Unity Biotechnology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
- Lead sponsor
- Unity Biotechnology, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 30, 2019
- Completion date
- August 7, 2020
- Enrollment
- 183 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.